Cytyc and Digene extend deadline again:
This article was originally published in Clinica
Cytyc has again extended the expiry date of its offer to buy Digene as the two companies respond to the US Federal Trade Commission's request for further information concerning the acquisition. The expiry date, which had previously been extended to April 11, is now April 25.
You may also be interested in...
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
Sawai’s sales increased on the back of a good performance from recently-launched products in the first nine months of its financial year. However, given the competitive environment the Japanese company is continuing to stick to its full-year forecasts.